Evidence map›Paper›PMID 41207950›Full record

ArticleAnnals of surgical oncology2026

Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy.

Robin D Wright, Pamela Lu, Laura Prakash, Yi-Ju Chiang, Ching-Wei D Tzeng, Jessica E Maxwell, Naruhiko Ikoma, Michael P Kim, Jeffrey E Lee, Matthew H G Katz and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Robin D WrightDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pamela LuDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Laura PrakashDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yi-Ju ChiangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ching-Wei D TzengDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jessica E MaxwellDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naruhiko IkomaDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael P KimDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey E LeeDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matthew H G KatzDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rebecca A SnyderDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rsnyder@mdanderson.org.ORCID http://orcid.org/0000-0002-2485-2481

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with pancreatic ductal adenocarcinoma (PDAC) experience an increased risk of venous thromboembolism (VTE), which is further potentiated by systemic chemotherapy. However, risk of VTE during preoperative therapy has not been well characterized to date. This study aimed to determine the prevalence and incidence of VTE in patients with PDAC treated with preoperative therapy with intent for surgery. PATIENTS AND

methodsWe performed a cohort study of all patients in a prospectively maintained database who had anatomically resectable or borderline resectable PDAC treated with chemotherapy with intent for surgery from 1 March 2016 to 31 December 2020. Primary outcomes were prevalent VTE at diagnosis or incident VTE during neoadjuvant therapy (NAT). Patients were censored at the date of surgery or when surgical intent was discontinued.

resultsOf 400 patients who met the inclusion criteria, 13 (3.3%) had prevalent VTE at diagnosis. After exclusions, the final study cohort included 332 patients. During NAT, 33 (9.9%) patients were diagnosed with incident VTE. Mesenteric venous thrombosis (MVT) was identified in 16 patients (4.8%), including 3 patients who experienced both MVT and VTE. Increased body mass index was the only factor analyzed that was associated with an increased risk of VTE in both unadjusted and adjusted analyses. Mean Khorana score between groups was not statistically different. Clinical characteristics, resection rates, and overall survival (OS) of patients with and without VTE were similar.

conclusionsIn a cohort of patients with locoregional PC treated with NAT, 3.3% had prevalent VTE at diagnosis and 9.9% had incident VTE. These data provide the basis for studying the effectiveness of VTE prophylaxis in this high-risk population.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalNeoadjuvant TherapyPancreatic NeoplasmsVenous ThromboembolismAgedFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPrognosisProspective StudiesRisk FactorsSurvival RateDeep vein thrombosisNeoadjuvant therapyPancreatic cancerPulmonary embolismVenous thromboembolism

Identifiers

PMID41207950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.